Company Filing History:
1 out of 1 
1 out of 20 Years Active: 2021
Title: Jens Gesche: Innovator in Tumor Marker Research
Introduction
Jens Gesche is a notable inventor based in Tuebingen, Germany. He has made significant contributions to the field of medical research, particularly in the development of tumor markers. His work focuses on innovative solutions that can aid in the diagnosis and treatment of cancer.
Latest Patents
Jens Gesche holds a patent for a tumor marker related to rhabdomyosarcoma. The patent describes a nucleic acid molecule that encodes a splice variant of the human P2RX7 receptor. This invention includes nucleic acid molecules derived from the original, a recombinant vector containing these molecules, and a host that expresses the encoded polypeptide. Additionally, it covers a binding molecule that interacts with the polypeptide, a pharmaceutical composition that includes this binding molecule, and methods for producing the isolated polypeptide.
Career Highlights
Throughout his career, Jens Gesche has worked with esteemed institutions such as Eberhard Karls Universität Tuebingen Medizinische Fakultät and Deutsches Krebsforschungszentrum Stiftung Des Öffentlichen Rechts. His research has contributed to advancements in cancer diagnostics and therapeutics.
Collaborations
Jens has collaborated with notable colleagues, including Sorin Armeanu-Ebinger and Guido Seitz. These partnerships have enhanced the impact of his research and innovations in the medical field.
Conclusion
Jens Gesche's work exemplifies the importance of innovation in medical research, particularly in the fight against cancer. His contributions through patents and collaborations continue to pave the way for advancements in tumor marker development.